

Share patents, and they shall be given you:

An empirical study on consequences of patent commons

Tohru Yoshioka-Kobayashi (Ph.D., The University of Tokyo)

t-koba@tmi.t.u-tokyo.ac.jp

Joint work with Akiko Segawa (Nomura Research Institute, Inc.)
and Toshiya Watanabe (Ph.D., The University of Tokyo)



Patent commons: A contradicting behavior?

Nature of patents

Disclosure of inventions



Granted exclusivity for
the limited period



Revenues from dominance

Patent commons (Patent sharing with indefinite firms)

Attract competitors



No exclusivity

Several recent cases of patent commons

Year	Patent holder	Technology	# patents	Type
2005	IBM and others	Open source software	529	NA
2008	IBM and others	Energy/clean tech.	100	NA
2013	Google	Energy/clean tech.	150	NA
2014	Tesla	Electric vehicle	All	NA
2015	Toyota Motors	Fuel-cell vehicle and its infrastructure	5680	RF
2015	Panasonic	Internet of things	50	RF
2015	Daikin	Refrigerant for air conditioners	100	RF

NAP: Non-assertion patent declaration

RF: Royalty free license offering (= need to sign a contract)

(Source) Segawa (2016), modified by Authors

Major motivations of patent commons

Expecting financial return

Non-financial return

Peripheral technology

Cost cutting:
 Patent donation to non-profit organizations

Benefit: Reduce patent maintenance costs and get tax reductions

Innovation catalyzing:
 Patent donation to non-profit organizations

Benefit: Strengthen research network, speed up innovation

Core technology

Profit making:
 Open source strategy or setting industry strategy

Benefit: Improve product or network effect

Technology providing:
 Free-license to certain geographical regions or for certain application
Benefit: Serve society, or earn reputation


Patent commons as a strategic tool?

Potential consequences of patent commons - 1: Hard to gain financial returns even in licensing strategy

- Negative evidences in outbound technology (=licensing and selling of patents)
 - Michelino, Caputo, Cammarano, & Lamberti (2014)
 - Examined a panel data of 126 global pharmaceutical firms
 - Licensing-out/selling-out of patents lead **negative financial performance**
 - Mazzola, Bruccoleri, & Perrone (2012)
 - Examined a panel data of 105 NASDAQ listed manufacturing equipment firms
 - # of licensing-out and selling-out **decrease financial performance** and **increase # of new product introductions**
- Difficulty of outbound open innovation (Helfat & Quinn, 2006)
- Biased by market losers? or bring non-financial returns?

Potential consequences of patent commons - 2: Knowledge retrievals

- Originating firms of knowledge spillovers learn from recipients (Yang et al., 2010; Yoneyama, 2013; Alnuaimi & George, 2016; Yoshioka-Kobayashi & Watanabe, 2018)



- These firms show high market value (Belenzon, 2012)

Theoretical background:

Why knowledge retrievals are important?


- Firms face difficulty in learning knowledge in unfamiliar technology fields
- Some firms are superior in new technological knowledge absorption = Absorptive capacity (Cohen & Levinthal, 1990)
 - Knowledge base determines the capacity



- Thus... M&As are not always succeeded
 - Technology absorption by M&As are more likely to succeed when acquires have sufficient knowledge base (Desyllus & Hughes, 2010)

In reality: Less-valuable patents provided

- Patents in Eco Patent Commons are less valuable than similar ones (Hall & Helmers, 2013)



Controls - 1:
Patents by Eco-Patent entrants

Controls - 2:
Patents share same IPCs with Eco-Patents, filed by firm

They concluded Eco-Patents did not contribute to innovation

What we do not know...

- Do patent commons have the positive impact?

Yes

- Change technological trajectory (attract other R&D oriented firms)
- Increase technological productivity of entrants (knowledge retrieval)



Patent commons motivate further technology development

No

- Only free-riders follow (only attract non-R&D-intensive firms)
- Few knowledge return



Patent commons send a negative signal that focal inventions are less valuable


Observations

- Treated: 498 U.S. granted patents from IBM later committed to Patent Commons (established in 2005)
 - Filed between 1988 and 2002 in USPTO
 - 50 lack exact matched control groups: 448 are used in matching analysis
- Control groups: granted patents from IBM
 - with exact same application year and combination of IPC subclasses
 - the nearest in # claims
 - randomly selected 8 patterns of control groups
 - By limiting to patents from IBM, we exclude an influence from IBM's technological reputation


Measurements of the value of patents

- Forward citations: a proxy of the value of patents and knowledge flow
 - Patents disclose referred (related) patented inventions
 - A proxy of knowledge flow (Jaffe et al., 2000; Duguet & MacGarvie, 2005)
 - But a bit noisy (see, Jaffe & de Rassenfosse, 2017)
 - Valuable inventions attract competitors
 - Competitors develop subsequent inventions and cite focal inventions
 - At least, forward citations indicate the technological impact (Albert et al., 1991; Benson & Magee, 2015)
 -and often correlate with commercial value (U.S. patents: Lanjouw & Schankerman, 1999; Bessen, 2008. European patents: Harhoff et al., 1999; Harhoff et al., 2003)

Identification strategy: Difference-in-difference analysis




Terms: Self forward citation and external forward citation



- Self forward citations: Subsequent patents filed by IBM
- External forward citations: Subsequent patents filed by other than IBM

Descriptive statistics (Average forward citations): Commons patents are less valuable


- Commons patents received fewer forward citations
 - IBM offered less valuable patents to Commons




Descriptive statistics (Average forward citations by periods)

Before commons

Forward citation
between '02-'04



Forward citation
between '06-'08



After commons


Descriptive statistics (Average forward citations by periods)



*90% of control and treated patents have no additional self-citations

Econometric analysis results: Patent Commons increases self forward citations

- Estimated impact of being in Commons
 - Cluster robust OLS regression results in a randomized control group:




*** significant at 0.1% level in the worst case, n.s. not significant (n=878 - 884 : depend on randomize groups)

Consequence of patent commons:

- Patent commons revive unfocused technologies and stimulate further development within the entrant firm
 - Probably, patent commons stimulate organizational learning from external followers: Knowledge retrievals (Alnuaimi & George, 2016), or "learning-by-disclosure" (Yoneyama, 2013)
- No significant external impact
 - Not statistically significant, but commons potentially reduce external forward citations just after the entry


What happened?

- Stimulate knowledge retrieval?
 - Identification strategy:
Does self forward citations of commons refer more diversified knowledge sources than those of control groups?



What happened?

- IBM's subsequent patents of Commons are more likely to refer various firms' knowledge



Why? - Several interpretations

- Software engineer communities were more likely to give feedback or share technological knowledge with IBM after Patent Commons



- IBM engineers were motivated to develop improved inventions to maintain competitiveness and, thus, become explorative




Consequence of Patent Commons

- A measure to learn from competitors and to stimulate internal development
- Even unfocused inventions can attract subsequent inventions
- There is a direct return from Commons
 - Probably, Commons are also beneficial to a technology community (future research)


Managerial implications - 1 (Static view)

- Strategic disclosure to improve internal technology development by stimulating knowledge retrieval
- Contribute to;
 - utilize underused technological assets,
 - develop technology absorptive capacity, and
 - learn from competitors.



Managerial implications - 2 (Dynamic view)

- In the "Connected" society, firms need to learn more various technological knowledge
 - Acquisitions are not always good solutions: Fail to absorb knowledge
- Co-opetitions (=coordination & competition: Tsai, 2002) become more important?



- Albert, M. B., Avery, D., Narin, F., & McAllister, P. (1991). Direct validation of citation counts as indicators of industrially important patents. *Research Policy*, 20(3), 251-259.
- Alnuaimi, T. & George, G. (2016). Appropriability and the retrieval of knowledge after spillovers. *Strategic Management Journal*, 37(7), 1263-1279.
- Belenzon, S. (2012). Cumulative innovation and market value: Evidence from patent citations. *The Economic Journal*, 122(559), 265-285.
- Benson, C. L., & Magee, C. L. (2015). Technology structural implications from the extension of a patent search method. *Scientometrics*, 102(3), 1965-1985.
- Bessen, J. (2008). The value of US patents by owner and patent characteristics. *Research Policy*, 37(5), 932-945.
- Cohen, W. M., & Levinthal, D. A. (1990). Absorptive capacity: A new perspective on learning and innovation. *Administrative Science Quarterly*, 35, 128-152.
- Desyllas, P., & Hughes, A. (2010). Do high technology acquirers become more innovative?. *Research Policy*, 39(8), 1105-1121.
- Duguet, E., & MacGarvie, M. (2005). How well do patent citations measure flows of technology? Evidence from French innovation surveys. *Economics of Innovation and New Technology*, 14(5), 375-393.
- Hall, B. H., & Helmers, C. (2013). Innovation and diffusion of clean/green technology: Can patent commons help?. *Journal of Environmental Economics and Management*, 66(1), 33-51.
- Harhoff, D., Narin, F., Scherer, F. M., & Vopel, K. (1999). Citation frequency and the value of patented inventions. *Review of Economics and Statistics*, 81(3), 511-515.
- Harhoff, D., Scherer, F. M., & Vopel, K. (2003). Citations, family size, opposition and the value of patent rights. *Research Policy*, 32(8), 1343-1363.
- Helfat, C.E.C., & Quinn, J.B. (2006). Review: Open innovation: The new imperative for creating and profiting from technology by Henry Chesbrough. *Academy of Management Perspectives*, 20(2), 86-88.
- Jaffe, A. B., Trajtenberg, M., & Fogarty, M. S. (2000). Knowledge spillovers and patent citations: Evidence from a survey of inventors. *American Economic Review*, 90(2), 215-218.
- Jaffe, A. B., & De Rassenfosse, G. (2017). Patent citation data in social science research: Overview and best practices. *Journal of the Association for Information Science and Technology*, 68(6), 1360-1374.
- Lanjouw, J. O., & Schankerman, M. (1999). The quality of ideas: measuring innovation with multiple indicators. National bureau of economic research, NBER Working Paper Series No. w7345.

- Mazzola, E., Bruccoleri, M., & Perrone, G. (2012). The effect of inbound, outbound and coupled innovation on performance. *International Journal of Innovation Management*, 16(6), 1240008-1-27.
- Michelino, F., Caputo, M., Cammarano, A., Lamberti, E. (2014). Inbound and outbound open innovation: Organization and performances. *Journal of Technology Management & Innovation*, 9(3), 65-82.
- Segawa, A. (2016). *An impact of royalty free patent license commitments on knowledge spillovers*. Master thesis, Dept. of Technology Management for Innovation, the Univ. of Tokyo. (瀬川晶子(2016)「特許無償開放が知識スピルオーバーに与える影響」東京大学大学院工学系研究科技術経営戦略学専攻修士論文.)
- Tsai, W. (2002). Social structure of “coopetition” within a multiunit organization: Coordination, competition, and intraorganizational knowledge sharing. *Organization Science*, 13(2), 179-190.
- Yang, H., Phelps, C., & Steensma, H.K. (2010). Learning from what others have learned from you: The effects of knowledge spillovers on originating firms. *Academy of Management Journal*, 53(2), 371-389.
- Yoshioka-Kobayashi, T., & Watanabe, T. (2018). A technological return from knowledge spillovers to originating firms: A new strategic tool or an unintentional side effect? Portland International Conference of Management of Engineering and Technology, Proceedings of PICMET 2018 (Honolulu, 20-24 August, 2018). (初期の成果として吉岡（小林）徹(2017)「アウトバウンド&インバウンド型の技術イノベーション：スピルオーバーした技術知識が元の組織に及ぼす影響についての試行的分析」『日本知財学会誌』14巻1号25頁-42頁)
- Ziegler, N., Gassmann, O., & Friesike, S. (2014). Why do firms give away their patents for free? *World Patent Information*, 37, 19-25.

APPENDIX

Other major (& old) cases of patent commons

Year	Patent holder	Technology	# patents	Type
1970	Dolby	Noise-reduction technology	N/A	NAP
1999	DuPont	N/A	N/A (valued at 64M USD)	D
2000	Procter & Gamble	Aspirin drug	196	D
2005	Sun Microsystems	Operating software	1670	NAP
2008	GlaxoSmithKline	Tropical diseases drug	800	RF

NAP: Non-assertion patent declaration

D: Donation to non-profit organization

RF: Royalty free license offering (= need to sign a contract)

(Source) Ziegler, Gassmann, & Friesike (2014)

Main analysis & Robustness check

- Estimated difference in forward citations (Table 1)
 - Difference-in-difference analysis
- Estimated using 8 randomized control groups (Table 2)
- Estimated # forward citations by periods (Table 3)

- Dataset are obtained from:
 - Patents View (USPTO)

Table 1. Estimation of forward citation growth (OLS: Randomized control group 1)

VARIABLES	Self forward citation growth to 02-04			External forward citation growth to 02-04		
	06-08	09-11	12-14	06-08	09-11	12-14
Commons dummy	1.045*** (0.179)	0.464*** (0.0929)	-0.381*** (0.0946)	-0.702* (0.358)	-0.221 (0.317)	-0.123 (0.298)
2005 – application year	-0.0201 (0.0265)	-0.0104 (0.0173)	-0.0132 (0.0135)	-0.00564 (0.0841)	-0.00303 (0.0706)	-0.0569 (0.0632)
# self forward citation (02-04)	-0.327** (0.147)	-0.788*** (0.0331)	-0.860*** (0.0448)	0.142 (0.180)	0.302* (0.156)	0.291** (0.146)
# external forward citation (02-04)	0.0812*** (0.0210)	0.0235*** (0.00744)	-0.00411 (0.00556)	-0.338*** (0.0720)	-0.552*** (0.0606)	-0.615*** (0.0589)
Year gap between filing and grant	-0.0117 (0.0614)	0.0405 (0.0731)	-0.0131 (0.0433)	-0.361*** (0.124)	-0.136 (0.118)	-0.0436 (0.0927)
# inventors	-0.0309 (0.0528)	0.0316 (0.0264)	-0.00678 (0.0169)	0.101 (0.122)	-0.106 (0.110)	-0.0668 (0.102)
# claims	0.0103 (0.0102)	-0.00152 (0.00455)	0.000529 (0.00330)	0.0198 (0.0220)	0.0201 (0.0225)	0.0248 (0.0186)
# IPCs	0.0185 (0.137)	-0.0278 (0.127)	0.131 (0.112)	0.823 (0.525)	0.529 (0.393)	0.243 (0.323)
# backward citations	-0.00577 (0.00572)	-0.00424 (0.00295)	-0.00498** (0.00248)	-0.0171 (0.0145)	0.0116 (0.0188)	0.0113 (0.0193)
Constant	0.0838 (0.472)	0.140 (0.271)	0.476** (0.222)	0.932 (1.017)	0.481 (0.961)	0.882 (0.972)
Observations	884	884	884	884	884	884
R-squared	0.114	0.516	0.579	0.178	0.399	0.475

Robust standard errors in parentheses *** p<0.01, ** p<0.05, * p<0.1

Table 2. Estimation of forward citation growth (OLS: Comparison between randomized groups)

		Group 1	Group 2	Group 3	Group 4	Group 5	Group 6	Group 7	Group 8
Self	06-08	1.045***	1.023***	0.928***	1.046***	1.114***	1.053***	0.993***	1.032***
		(0.179)	(0.181)	(0.199)	(0.174)	(0.178)	(0.180)	(0.194)	(0.187)
	09-11	0.464***	0.359***	0.422***	0.422***	0.397***	0.433***	0.344***	0.360***
		(0.093)	(0.104)	(0.104)	(0.090)	(0.105)	(0.091)	(0.107)	(0.101)
	12-14	-0.381***	-0.457***	-0.404***	-0.401***	-0.414***	-0.381***	-0.349***	-0.447***
		(0.095)	(0.089)	(0.075)	(0.063)	(0.079)	(0.072)	(0.072)	(0.094)
External	06-08	-0.702*	-0.829**	-0.919**	-1.112***	-1.132***	-0.512	-0.49	-0.663*
		(0.358)	(0.337)	(0.370)	(0.376)	(0.371)	(0.342)	(0.325)	(0.370)
	09-11	-0.221	-0.143	-0.423	-0.505	-0.384	-0.0667	0.0616	-0.335
		(0.317)	(0.316)	(0.386)	(0.405)	(0.326)	(0.320)	(0.286)	(0.394)
	12-14	-0.123	-0.206	-0.54	-1.102**	-0.682*	-0.139	-0.105	-0.551
		(0.298)	(0.309)	(0.428)	(0.474)	(0.353)	(0.301)	(0.294)	(0.431)
		884	879	883	882	879	878	881	882

Table 3. Estimation of forward citations (Negative binomial GML: in Randomized control group 1)

VARIABLES	# self forward citations			# external forward citations		
	06-08	09-11	12-14	06-08	09-11	12-14
Commons dummy	0.726*** (0.121)	0.692*** (0.147)	-1.402*** (0.230)	-0.0670 (0.0820)	0.0925 (0.0949)	0.121 (0.0993)
2005 – application year	-0.0467** (0.0203)	-0.0273 (0.0248)	-0.0257 (0.0385)	-0.00815 (0.0156)	-0.0165 (0.0189)	-0.0324 (0.0198)
# self forward citation (02-04)	0.255*** (0.0347)	0.221*** (0.0482)	0.255*** (0.0815)	0.0957*** (0.0302)	0.134*** (0.0325)	0.109*** (0.0309)
# external forward citation (02-04)	0.0435*** (0.00672)	0.0299*** (0.00795)	0.0137 (0.0128)	0.0862*** (0.00686)	0.0838*** (0.00794)	0.0797*** (0.00764)
Year gap between filing and grant	0.0253 (0.0454)	0.0826 (0.0751)	0.0543 (0.0738)	-0.0680** (0.0285)	-0.0251 (0.0323)	-0.0268 (0.0360)
# inventors	-0.0173 (0.0340)	0.0324 (0.0348)	-0.0354 (0.0506)	0.0149 (0.0227)	-0.0151 (0.0262)	0.00365 (0.0304)
# claims	0.00688 (0.00525)	-0.00374 (0.00636)	0.0102 (0.00903)	0.00360 (0.00412)	0.000708 (0.00452)	0.00933* (0.00546)
# IPCs	0.119 (0.0996)	-0.0432 (0.178)	0.600** (0.259)	0.130 (0.0950)	0.164 (0.103)	0.0684 (0.112)
# backward citations	-0.00889 (0.00593)	-0.0112 (0.00797)	-0.0294* (0.0152)	-0.00233 (0.00299)	0.00123 (0.00466)	0.000355 (0.00613)
Constant	-0.474 (0.344)	-1.093** (0.152)	1.554*** (0.575)	-0.0512 (0.0708)	0.239*** (0.291)	0.413 (0.0760)
Observations	884	884	884	884	884	884
Pseudo R2	0.0787	0.0493	0.0700	0.0832	0.0702	0.0593
Log Lik	-1317	-940.8	-510.4	-2102	-1886	-1823

Robust standard errors in parentheses *** p<0.01, ** p<0.05, * p<0.1

Additional analysis

- Used 10,087 self forward citations of treatments and controls (filed from 1992 to 2018)
 - In this selection, we included examiner forward citations
- Calculated the number of applicants appeared in their backward citations
 - In this calculation, we excluded examiner backward citations
 - We only used patents filed by organization (excluded individuals)
- Poisson model regress results are shown at Table 4

Table 4. Estimation of # applicants in backward citations of forward citations of treatments and controls (Poisson GML)

	# applicants in backward citations (by application year of forward citation patents)			
	'02-04	'06-08	'09-11	'12-14
Forward citations of Commons (dummy)	1.283*** (0.0347)	1.396*** (0.0304)	1.796*** (0.0280)	1.553*** (0.0227)
Application year	1.069*** (0.0173)	1.259*** (0.0165)	0.995 (0.00940)	0.968*** (0.00809)
# Claims	1.007*** (0.000870)	1.014*** (0.000711)	1.018*** (0.000534)	1.020*** (0.000719)
Observations	1,461	1,541	1,915	1,713
Pseudo R2	0.0124	0.0335	0.0597	0.0397
Log Likelihood	-6421	-10018	-18204	-18867

Incident rate ratio in parentheses *** p<0.01, ** p<0.05, * p<0.1